First Horizon Advisors Inc. Sells 65 Shares of Humana Inc. (NYSE:HUM)

First Horizon Advisors Inc. lowered its stake in Humana Inc. (NYSE:HUM) by 19.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 263 shares of the insurance provider’s stock after selling 65 shares during the period. First Horizon Advisors Inc.’s holdings in Humana were worth $120,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Rakuten Securities Inc. purchased a new position in shares of Humana during the fourth quarter valued at about $25,000. Gradient Investments LLC lifted its stake in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 40 shares during the period. Cetera Trust Company N.A purchased a new position in shares of Humana in the 4th quarter valued at approximately $28,000. Nvwm LLC boosted its position in shares of Humana by 41.0% during the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Humana in the fourth quarter worth $55,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM opened at $319.23 on Tuesday. The firm has a fifty day simple moving average of $323.55 and a two-hundred day simple moving average of $387.14. The firm has a market cap of $38.47 billion, a PE ratio of 19.88, a P/E/G ratio of 1.86 and a beta of 0.49. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $541.21.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.38 earnings per share. On average, equities analysts anticipate that Humana Inc. will post 16.18 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.11%. Humana’s dividend payout ratio (DPR) is 22.04%.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HUM has been the topic of a number of research reports. Bank of America restated a “neutral” rating and set a $342.00 target price (down previously from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Argus cut shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Raymond James initiated coverage on shares of Humana in a report on Friday, March 22nd. They set a “market perform” rating for the company. Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $595.00 to $360.00 in a research report on Thursday, January 25th. Finally, Barclays cut their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.